Home › NDC Lookup › RxCUI directory › RxCUI 2174804

Trastuzumab-anns 21 MG/ML Injectable Solution — RxCUI 2174804

Name: Trastuzumab-anns 21 MG/ML Injectable Solution (RxCUI 2174804)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2174804 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2174804

Official nameTrastuzumab-anns 21 MG/ML Injectable Solution

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known astrastuzumab-anns 420 MG per 20 ML Injectable Solution; trastuzumab-anns 420 MG in 20 mL Injectable Solution

FDA products mapped2

Package NDCs mapped4

Reported Medicaid activity (SDUD)5,103 prescriptions · 28 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Trastuzumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Trastuzumab is used for more than just breast cancer. It treats HER2-positive breast cancer — both early-stage (after surgery) and metastatic (spread) breast cancer. It's also appr...
What exactly is trastuzumab used for — is it just for breast cancer?
No, trastuzumab is not a pill. It's given as an IV infusion — a drip into a vein — at your cancer center or infusion clinic. Your very first infusion is given slowly over 90 minute...
How will I receive this medication? Do I take it as a pill?

📖 Read our full Trastuzumab Injection guide →

🕸️ Concept Web — How Trastuzumab-anns 21 MG/ML Injectable Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Trastuzumab-anns 21 MG/ML Injectable Solution RxCUI 2174804 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Trastuzumab 224905 IN
- Trastuzumab-anns 2174802 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Kanjinti 2174805 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Trastuzumab Injectable Solution 377216 SCDF
- Trastuzumab-anns Injectable Solution 2648435 SCDFP
- Trastuzumab Injectable Product 1162762 SCDG
- Trastuzumab-anns Injectable Product 2662333 SCDGP
- Trastuzumab Injectable Solution [Kanjinti] 2174807 SBDF
- Trastuzumab-anns Injectable Solution [Kanjinti] 2657424 SBDFP
- Kanjinti Injectable Product 2174808 SBDG
- Injectable Solution 316949 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Trastuzumab-anns 21 MG/ML 2174803 SCDC
- Trastuzumab-anns 21 MG/ML Injectable Solution [Kanjinti] 2174809 SBD
- Trastuzumab-anns 21 MG/ML [Kanjinti] 2174806 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Trastuzumab-anns 21 MG/ML SCDC · 2174803
Trastuzumab Injectable Solution SCDF · 377216
Trastuzumab-anns Injectable Solution SCDFP · 2648435
Trastuzumab Injectable Product SCDG · 1162762
Trastuzumab-anns Injectable Product SCDGP · 2662333

Brand-Name Concepts

Trastuzumab-anns 21 MG/ML Injectable Solution [Kanjinti] SBD · 2174809
Trastuzumab-anns 21 MG/ML [Kanjinti] SBDC · 2174806
Trastuzumab Injectable Solution [Kanjinti] SBDF · 2174807
Trastuzumab-anns Injectable Solution [Kanjinti] SBDFP · 2657424
Kanjinti Injectable Product SBDG · 2174808
Kanjinti BN · 2174805

📦 FDA Products & Package NDCs

2 products · 4 package NDCs

4 package NDCs map to RxCUI 2174804 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
55513-0132-01	1 VIAL, MULTI-DOSE in 1 CARTON (55513-132-01) / 20 mL in 1...	Kanjinti	Amgen, Inc	2019-06-11
55513-0132-21	1 VIAL, MULTI-DOSE in 1 CARTON (55513-132-21) / 20 mL in 1...	Kanjinti	Amgen, Inc	2025-07-01
55513-0141-01	1 VIAL, SINGLE-DOSE in 1 CARTON (55513-141-01) / 7.15 mL in...	Kanjinti	Amgen, Inc	2019-10-28
55513-0141-21	1 VIAL, SINGLE-DOSE in 1 CARTON (55513-141-21) / 7.15 mL in...	Kanjinti	Amgen, Inc	2025-07-01

Observed labelers: Amgen, Inc (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
Q5117	Inj., kanjinti, 10 mg	4	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.